Results 121 to 130 of about 1,303,482 (284)

DISPERSIÓN DEL INTERVALO QT CORREGIDO EN LA EVOLUCIÓN DE PACIENTES CON SÍNDROMES CORONARIOS AGUDOS / Corrected QT interval dispersion in the evolution of patients with acute coronary syndromes [PDF]

open access: yesCorSalud, 2011
Introduction and Objectives: Acute myocardial infarc-tion remains a major challenge for health systems. In the classic concept of the ischemic cascade, the earliest event is the QT interval prolongation, which was previously reported in patients with ...
Carlos J. Fabelo Mora   +5 more
doaj  

Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio‐oncology Registry

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, offering improvements in survival across various malignancies. However, their toxicities pose a major challenge for cardio‐oncology units. Despite their growing importance, data on effectiveness of such specialized units in mitigating ICI‐associated ...
Elias Haj‐Yehia   +6 more
wiley   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe   +4 more
wiley   +1 more source

Effects of Neostigmine and Sugammadex on QT Interval and QT Dispersion [PDF]

open access: yes, 2016
Dispersion of QT dispersion(QTD)in 12-lead electrocardiogram is a useful index for assessment of ventricular arrhythmia risk and cardiovascular event. To determine the effects of reversal of nondepolarizing neuromuscular blockade on cardiovascular event,
Takasusuki, Toshifumi   +3 more
core   +1 more source

Signal detection and characterisation of a novel drug–drug interaction between methadone and a synthetic cannabinoid receptor agonist

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Little is known about how synthetic cannabinoid receptor agonist (SCRA) co‐use with other psychoactive substances may exacerbate risk of death. This study aimed to characterise the polypharmacy of deaths where SCRAs were detected at post‐mortem, investigate the cardiotoxicity of SCRAs and probe their inhibition of human ether‐a ...
Kirsten L. Rock   +9 more
wiley   +1 more source

Hypoglycaemia care: Time to modernise our treatment standards

open access: yesDiabetic Medicine, EarlyView.
This editorial argues that hypoglycaemia self care should move beyond ‘any sugar will do’ and define what good recovery after treatment should involve. It proposes recovery‐focused standards using CGM metrics, such as time‐in‐range and repeat lows after treatment, alongside participant‐reported recovery, so existing and emerging approaches, including ...
David Russell‐Jones, Julia K. Mader
wiley   +1 more source

Intravenous Oxytocin Does Not Affect Glucose‐Regulating Hormones or Markers of Bone Turnover During Graded Glucose Infusion in Healthy Men

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim Oxytocin has been proposed to exert glucose‐stabilising effects via modulation of pancreatic hormone secretion and to play a role in bone homeostasis. However, human data under controlled conditions are limited. We investigated the effects of intravenously infused oxytocin during a graded glucose infusion on glucose‐regulating hormones and
Vivian Kliim‐Hansen   +9 more
wiley   +1 more source

Prognostic significance of prolonged corrected QT interval in cerebral contusion. [PDF]

open access: yesIndian J Med Res, 2023
Yavuz AY, Baskurt O, Kurtulus Y, Avci I.
europepmc   +1 more source

Safety, Tolerability, Pharmacokinetics and Exploratory Pharmacodynamics of Melanin‐Concentrating Hormone Receptor‐1 Antagonist RGH‐706 in Healthy and Overweight or Obese Men

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim This Phase 1 program evaluated the safety, tolerability, pharmacokinetics and exploratory pharmacodynamics of the novel melanin‐concentrating hormone receptor‐1 antagonist RGH‐706. Methods Study A was a first‐in‐man, randomized trial comprising a double‐blind, placebo‐controlled single‐ascending‐dose part (0.1–162.5 mg) and a two‐way ...
Thomas Brevig   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy